Across TCGA pan-cancer cohorts, MIER1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MIER1 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MIER1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MIER1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where MIER1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.973	0.829	.002	30	view →
LSCC	DFS	Median	II,III,IV	0.509	0.861	.002	23	view →
PDAC	OS	Median	II,III,IV	0.357	0.583	.010	5	view →
HNSC	DFS	Median	III,IV	0.527	0.707	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MIER1 tumor-vs-normal RNA expression · all MIER1 data types